---
created: 2025-04-13
updated: 2025-04-13T10:52
id: LA_eGDPrp0
specialty: pharmaco
specialty_id: 245
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/amboss::hematonco
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::07-anticoagulants
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::05-direct-factor-xa-inhibitors
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::13-hematology-oncology::11-hemostasis
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::directthrombininhibitors-directfactorxainhibitors
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::10-heme::factor-xa-inhibitors-(apixaban,-rivaroxaban,-edoxaban)
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::03-blood-&-inflammation::01-anticoagulants-&-thrombolytics::01-heparin,-lmwh,-fondaparinux,-direct-thrombin-inhibitors,-xa-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::2000-2999::2133
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::14000-14999::14741
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15390
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18686
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - "source/ak-step2-v11:": 
  - theme/amboss
  - "source/ak-step2-v11:": 
  - theme/amboss::im
  - "source/ak-step2-v11:": 
  - theme/amboss::surgery"
type: flashcard
---

# Question
Do direct factor Xa inhibitors (apixaban, rivaroxaban) require lab monitoring?   **No**

---

# Answer
prevent conversion of prothrombin II to thrombin IIa